Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura did not meet the non-inferiority margin of the coefficient of fat absorption primary endpoint in the Result Phase 3 clinical study of exocrine pancreatic insufficiency due to cystic fibrosis.
For other potential major movers in the health care field coming this month, check out the biopharma catalyst calendar.
Although a proportion of patients randomized to Sollpura maintained or improved their coefficient of fat absorption from baseline in the study, a higher proportion of patients experienced a worsening. At the same time, Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption.
Looking ahead, the company plans to evaluate the full data outputs but will suspend further clinical development of Sollpura, including the 20-week extension period of the study.
Craig Thompson, president and chief executive, commented:
We are greatly disappointed by the findings of the RESULT study. We would like to extend our deepest gratitude to the patients and their families, study investigators, and the cystic fibrosis community for the support they have provided in the clinical development of Sollpura.
Shares of Anthera were last seen down 81% at $0.50, with a consensus analyst price target of $3.79 and a 52-week range of $0.40 to $5.60.
24/7 Wall St.Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.